Offering Closed
PHARMACEUTICAL · REGULATION CROWDFUNDING
Lab-Based Diagnostic Testing Powered by AI and Real-World Data
20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab, we offer what is believed to be the first multi-cancer screening blood test in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. Due to our ability to scale our COVID testing operation, 2021 revenues exceeded $9 million with over $1 million in net profits for the year. This represents a more than 300% increase over 2020 revenues. As a result, we ranked no. 131 on the Inc. 5000 list of America’s fastest-growing companies in 2022. To grow our portfolio of tests, the Company has built a Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first accelerator facility for diagnostics start-ups. Our CLIAx is expected to help fuel our product and revenue growth for the next five years and already has two companies signed up to join.
Offering Closed
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
